Litcius/Paper detail

CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice

Daniel Stone, Kelly R. Long, Michelle A. Loprieno, Harshana S. De Silva Feelixge, Elizabeth J. Kenkel, R. Matt Liley, Stephen Rapp, Pavitra Roychoudhury, Thuy Nguyen, Laurence Stensland, Rossana Colón-Thillet, Lindsay M. Klouser, Nicholas D. Weber, Connie Le, Jessica Wagoner, Erin A. Goecker, Alvason Zhenhua Li, Karsten Eichholz, Lawrence Corey, D. Lorne Tyrrell, Alexander L. Greninger, Meei‐Li Huang, Stephen J. Polyak, Martine Aubert, John E. Sagartz, Keith R. Jerome

2020Molecular Therapy — Methods & Clinical Development93 citationsDOIOpen Access PDF

Abstract

gene editing for chronic HBV infections, and it suggests that with further optimization, this approach may offer a plausible way to treat or even cure chronic HBV infections.

Topics & Concepts

cccDNAVirologyHepatitis B virusCas9EntecavirBiologyAdeno-associated virusGenetic enhancementVirusGenome editingCRISPRPlasmidGeneRecombinant DNAVector (molecular biology)GeneticsLamivudineHBsAgCRISPR and Genetic EngineeringVirus-based gene therapy researchViral gastroenteritis research and epidemiology
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice | Litcius